Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Tristan Shaffer, MS"'
Autor:
Jarrod T. Smith, BA, Aneri Balar, MD, Dhairya A. Lakhani, MD, Christien Kluwe, MD, PhD, Zhiguo Zhao, MS, Prasad Kopparapu, PhD, Karinna Almodovar, PhD, Anel Muterspaugh, MPH, CPH, Yingjun Yan, MS, Sally York, MD, PhD, Leora Horn, MD, MSc, Sanja Antic, MS, Caterina Bertucci, MPA, Tristan Shaffer, MS, Lauren Hodsdon, MPH, Kavita Garg, PhD, Seyed Ali Hosseini, MD, PhD, Lee Lim, PhD, Evan Osmundson, MD, PhD, Pierre P. Massion, MD, Christine M. Lovly, MD, PhD, Wade Iams, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 3, Pp 100110- (2021)
Introduction: Blood-based next-generation sequencing assays of circulating tumor DNA (ctDNA) have the ability to detect tumor-associated mutations in patients with SCLC. We sought to characterize the relationship between ctDNA mean variant allele fre
Externí odkaz:
https://doaj.org/article/30a2425056284f07b711aa00850a555d
Autor:
Wade T. Iams, MD, Prasad R. Kopparapu, PhD, Yingjun Yan, MS, Anel Muterspaugh, MPH, Zhiguo Zhao, MS, Heidi Chen, PhD, Christopher Cann, MD, Sally York, MD, PhD, Leora Horn, MD, MS, Kristin Ancell, MD, Kenneth Wyman, MD, Caterina Bertucci, MPA, Tristan Shaffer, MS, Lauren A. Hodsdon, MPH, Kavita Garg, PhD, Seyed Ali Hosseini, MD, PhD, Lee P. Lim, PhD, Christine M. Lovly, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 1, Iss 2, Pp 100024- (2020)
Introduction: Most patients (70%) with limited-stage SCLC (LS-SCLC) who are treated with curative-intent therapy suffer disease relapse and cancer-related death. We evaluated circulating tumor DNA (ctDNA) as a predictor of disease relapse and death a
Externí odkaz:
https://doaj.org/article/4458f029679347a28119d2847325d282